Seizure susceptibility and mortality in mice that over-express amyloid precursor protein.
Alzheimer's disease and Fragile X syndrome both display synaptic phenotypes, and based on recent studies, likely share dendritic over expression of amyloid precursor protein (APP) and beta-amyloid (Abeta). In order to create a mouse model to specifically study the effects of APP and Abeta at synapses, we crossed Tg2576, which over-express human APP with the Swedish mutation (hAPPsw), with fmr-1 KO mice. The progeny, named FRAXAD, displayed increased mortality (23% by 30 days of age) compared to Tg2576 (3%) and WT and fmr-1 KO littermate controls (0%) consistent with a developmental defect. By 60 days of age, both the Tg2576 and FRAXAD mice approached a 40% mortality rate compared to 0% for WT and fmr-1 KO littermates. To understand the mechanism underlying increased mortality in APP over-expressing mice, we assessed seizure thresholds in response to pentylenetetrazol (PTZ). Both the Tg2576 and FRAXAD mice had a lower threshold to PTZ-induced seizures (average seizure score of >/=4.0) in comparison to nontransgenic littermates (average seizure score 1.9-2.9). Seizures are a major phenotype of AD, FXS, Down syndrome, autism and epilepsy, and these data suggested that developmental over-expression of dendritic APP or Abeta increased seizure susceptibility.
Westmark
Cara J
CJ
Department of Pathology & Laboratory Medicine, Waisman Center for Developmental Disabilities, University of Wisconsin Madison, WI 53705, USA. westmark@facstaff.wisc.edu
Westmark
Pamela R
PR
Beard
Ashley M
AM
Hildebrandt
Sharon M
SM
Malter
James S
JS
J Pharmacol Exp Ther. 2001 Sep;298(3):986-95
11504794
Neurobiol Aging. 2006 Dec;27(12):1740-50
16337035
Biochim Biophys Acta. 1995 Mar 14;1261(1):134-42
7893750
Am Fam Physician. 2003 Jan 15;67(2):325-32
12562154
PLoS Biol. 2007 Mar;5(3):e52
17298186
Brain Dev. 2005 Jun;27(4):246-52
15862185
Hum Mol Genet. 2000 May 1;9(8):1145-59
10767339
Brain Res. 1994 Dec 15;666(2):151-67
7882025
J Biol Chem. 1998 May 1;273(18):11100-6
9556595
Trends Neurosci. 1993 Oct;16(10):409-14
7504356
Proc Natl Acad Sci U S A. 1992 Oct 15;89(20):9439-43
1409654
Brain Res Mol Brain Res. 1995 Aug;32(1):36-44
7494461
EMBO J. 2005 Oct 19;24(20):3624-34
16193067
Neurobiol Dis. 2002 Aug;10(3):211-8
12270684
Neuroscience. 2001;103(4):1043-50
11301211
Neurobiol Aging. 2008 Jun;29(6):861-73
17331621
Neurosci Lett. 1990 Jul 17;115(1):97-102
2120637
J Neurosci. 1999 Sep 15;19(18):7793-803
10479682
Cell Death Differ. 1998 Oct;5(10):858-66
10203685
Epilepsia. 2000 Jan;41(1):19-23
10643918
Proc Natl Acad Sci U S A. 1992 Apr 1;89(7):2551-5
1557359
J Pharmacol Sci. 2005 Apr;97(4):461-71
15821343
Science. 1996 Oct 4;274(5284):99-102
8810256
Nat Med. 1995 Aug;1(8):829-32
7585189
Alzheimer Dis Assoc Disord. 1990 Winter;4(4):217-25
2264979
Dev Biol. 1994 Feb;161(2):597-603
8314003
Neurology. 2004 Oct 12;63(7):1155-62
15477531
Ann N Y Acad Sci. 2005 Jun;1048:149-65
16154929
J Neurochem. 1992 Oct;59(4):1316-24
1402883
Neurosci Lett. 2004 Sep 2;367(2):164-7
15331144
EMBO J. 1996 Mar 15;15(6):1265-74
8635459
Behav Brain Res. 2005 Feb 10;157(1):91-8
15617775
Brain Res. 1992 Oct 16;593(2):323-8
1450940